HeartBeam Cuts Q3 Loss as FDA Breakthrough Nod Sharpens Heart Attack Strategy

HeartBeam narrowed its third-quarter net loss to $3 million and advanced its heart attack assessment program with FDA Breakthrough Device Designation, positioning the company for a pivotal U.S. study in 2027.

Chicago Metrowire Staff
••Healthcare
HeartBeam Cuts Q3 Loss as FDA Breakthrough Nod Sharpens Heart Attack Strategy

HeartBeam Inc. (NASDAQ: BEAT) reported a third-quarter net loss of $3 million, or $0.05 per share, for the period ended Sept. 30, 2026, a sharp improvement from the $5.3 million, or $0.15 per share, loss recorded a year earlier. Operating expenses fell to $3.5 million from $5.3 million, and the cardiac care technology company held $6.1 million in cash and cash equivalents at quarter-end. The narrower loss matters because it shows HeartBeam is tightening its cost base while pursuing a regulatory pathway that could reshape how heart attacks are assessed outside of hospitals.

HeartBeam also raised roughly $4 million in net proceeds during the fourth quarter through the announcement date, lifting pro forma cash to about $10.1 million. Management now expects full-year 2026 net operating cash outflow of $12 million to $12.5 million. The capital position is central to the company's plans, since it must fund a pivotal U.S. study while keeping its operations lean.

Operationally, HeartBeam has narrowed its strategic focus to heart attack assessment. The company received U.S. Food and Drug Administration Breakthrough Device Designation and acceptance into the agency's Total Product Life Cycle Advisory Program, or TAP. Those designations are significant because they can give a device maker earlier and more frequent interaction with regulators, potentially smoothing the path toward market clearance for a technology aimed at detecting acute cardiac events.

The clinical evidence is building. HeartBeam completed enrollment of 486 patients in its HEADSTART-ACS study and reported positive results from its 132-patient ALIGN-ACS pilot study, which demonstrated higher specificity than standard 12-lead electrocardiograms with comparable sensitivity. Higher specificity could reduce false positives, a meaningful consideration for triage tools intended to help direct patients to appropriate care. HeartBeam plans to finalize the design of its U.S. pivotal study in the fourth quarter of 2026 and begin patient enrollment in the first quarter of 2027.

HeartBeam is developing what it describes as the first cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a 12-lead ECG. The platform received FDA clearance for arrhythmia assessment in December 2024 and for 12-lead ECG synthesis software in December 2025, with details available through the company's cleared indications for use. The company holds more than 20 issued patents related to technology enablement.

For investors, the quarter offers a clearer picture of a company trading near-term spending discipline for a longer-term bet on decentralized cardiac diagnostics. The latest news and updates relating to BEAT are available in the company's newsroom at https://ibn.fm/BEAT, and the full press release can be viewed at https://ibn.fm/8CLXO. The announcement was distributed through InvestorWire, a platform within the Dynamic Brand Portfolio at IBN.

Blockchain Registration

QR Code for Blockchain Registration